Coronavirus

Actions

UH Medical Center expected to receive shipment of experimental COVID-19 vaccine next week

University Hospitals Cleveland Medical Center.
Posted at 10:41 AM, Aug 24, 2020
and last updated 2020-08-24 10:41:40-04

CLEVELAND — The beginning of the clinical trial to test Pfizer and BioNTech’s COVID-19 vaccine is expected to begin next week at University Hospitals Cleveland Medical Center, according to news release from the hospital.

UH Medical center is the first hospital system in Northeast Ohio and one of approximately 120 sites around the world that will collectively enroll up to 30,000 participants for the Phase 2/3 clinical trial.

“This is encouraging news for Ohioans,” said Daniel I. Simon, MD, Chief Clinical & Scientific Officer and President, UH Cleveland Medical Center, in a news release. “We were among the first in the nation to test Remdesivir, the promising drug in the treatment of COVID-19, which enabled our community to benefit from our participation in the clinical trial program. And now once again, we are bringing our community another potential defense mechanism in our fight against the coronavirus – a vaccine candidate. The trial has been approved by the FDA and our Institutional Review Board. We are expecting shipment of the experimental vaccine and initiation of the trial in the next week.”

The Phase 2/3 study is designed to obtain the safety, immune response and efficacy data needed for regulatory review for this vaccine's development approach, which used mRNA packaged with coronavirus genes to generate the spike protein which is believed to generate protective antibodies, according to the release.

Researchers are looking to enroll non-pregnant adults from 18 to 85 years old. UH said because of the disproportionate occurrence of COVID-19 among people of color and the severity of the disease and the higher death rate, it plans to have diverse representation included in this study.

Those who are interested in participating in the study at UH Medical Center should call 612-524-9091.

RELATED: University Hospitals to participate in COVID-19 vaccine trials in Cleveland

Additional Coronavirus information and resources:

See complete coverage on our Coronavirus Continuing Coverage page.

Rebound Northeast Ohio News 5's initiative to help people through the financial impact of the coronavirus by offering one place to go for information on everything available to help and how to access it. We're providing resources on:

Getting Back to Work - Learn about the latest job openings, how to file for benefits and succeed in the job market.

Making Ends Meet - Find help on topics from rent to food to new belt-tightening techniques.

Managing the Stress - Feeling isolated or frustrated? Learn ways to connect with people virtually, get counseling or manage your stress.

Doing What's Right - Keep track of the way people are spending your tax dollars and treating your community.

We're Open! Northeast Ohio is place created by News 5 to open us up to new ways of thinking, new ways of gathering and new ways of supporting each other.

Click here for a page with resources including a COVID-19 overview from the CDC, details on cases in Ohio, a timeline of Governor Mike DeWine's orders since the outbreak, coronavirus' impact on Northeast Ohio, and link to more information from the Ohio Department of Health, the Cuyahoga County Board of Health, the CDC and the WHO.

See data visualizations showing the impact of coronavirus in Ohio, including county-by-county maps, charts showing the spread of the disease, and more.

The CDC and the Ohio Department of Health are now recommending the use of cloth face coverings in public to slow the spread of COVID-19.

Read more about the CDC's recommendation here. Here is a step-by-step guide on how to make a face mask from common household materials, without having to know how to sew.

View a global coronavirus tracker with data from Johns Hopkins University.

Download our streaming app on your favorite device.  Click here for more.

Download our streaming app on your favorite device. Click here for more.